Back to top
more

STERIS (STE)

(Real Time Quote from BATS)

$234.89 USD

234.89
98,096

-0.89 (-0.38%)

Updated Oct 2, 2024 03:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (50 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Insulet (PODD) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Insulet (PODD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

TFX or STE: Which is a Better Investment Pick Right Now?

by Zacks Equity Research

STERIS (STE) scores higher than Teleflex (TFX) when it comes to valuation and one-year price performance.

Steris (STE) Up 7.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

STERIS (STE) Q4 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

STERIS (STE) witnesses solid revenue growth across each of its operating segments in the reported quarter.

Steris (STE) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Steris (STE) delivered earnings and revenue surprises of 6.25% and 4.62%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Aurora Cannabis (ACB) in Q3 Earnings?

by Zacks Equity Research

Continued execution of consumer and medical strategies, launch of new products and strong international footprint are likely to aid Aurora Cannabis (ACB) in Q3.

Steris (STE) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Steris (STE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Core Business Unit Fuel McKesson (MCK) Q4 Earnings?

by Zacks Equity Research

Anticipated growth across core business unit and solid show by Medical Surgical and European Pharmaceutical Solutions is likely to aid McKesson's (MCK) Q4 earnings. However, rising costs might be a dampener.

What's in Store for Cardinal Health (CAH) in Q3 Earnings?

by Zacks Equity Research

Better-than-expected performance at Pharmaceutical and Medical segments and diverse product portfolio is likely to aid Cardinal Health (CAH) in Q3 earnings. However, stiff competition might play spoilsport.

What's in the Cards for DaVita (DVA) This Earnings Season?

by Zacks Equity Research

Better-than-expected performance at Kidney Care, strategic buyouts and international expansion might aid DaVita (DVA) in Q1. However, integration risks might be a dampener.

Masimo Gets CE Mark for ANI Module, Enhances Root Platform

by Zacks Equity Research

Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.

What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?

by Zacks Equity Research

Better-than-expected performance at Pharmaceutical Distribution and World Courier and higher revenues might aid AmerisourceBergen (ABC) in Q2 earnings. However, stiff competition might be a dampener.

Can Mass Cytometry Drive Fluidigm's (FLDM) Q1 Earnings?

by Zacks Equity Research

Better-than-expected performance at mass cytometry market and higher revenues is likely to aid Fluidigm's (FLDM) in Q1 earnings. However, sluggishness in microfluidics market remains a dampener.

DENTSPLY SIRONA (XRAY) Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Higher Consumable revenues, product innovation and focus on R&D likely to aid DENTSPLY SIRONA (XRAY) in Q1 earnings. However, contraction is gross margin might be a dampener.

Integer Holdings (ITGR) Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Better-than-expected performance at C&V and Cardiac & Neuromodulation product lines and higher revenues might aid Integer Holdings (ITGR) in Q1. But decline in non-medical sales might be a dampener.

Here's Why You Should Hold on to STERIS (STE) Stock Now

by Zacks Equity Research

STERIS (STE) has been gaining investors' confidence on consistently positive results.

STERIS (STE) Margin Pressure Hurts, Strategic Growth High

by Zacks Equity Research

Mounting operating expenses are weighing on the bottom line of STERIS (STE).

Why Is Steris (STE) Up 1.2% Since Last Earnings Report?

by Zacks Equity Research

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates

by Zacks Equity Research

STERIS (STE) continues to gain from strength in all business segments in Q3.

Steris (STE) Matches Q3 Earnings Estimates

by Zacks Equity Research

Steris (STE) delivered earnings and revenue surprises of 0.00% and 1.21%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Steris (STE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Invest in STERIS (STE) Stock Right Now

by Zacks Equity Research

With the acquisition of U.K.-based outsourced sterilization services provider Synergy Health, STERIS (STE) has become the global leader in infection prevention and sterilization.

STERIS Rides on Favorable Industry Trends, Rivalry a Concern

by Zacks Equity Research

STERIS (STE) is currently displaying strong top-line growth on encouraging market trends along with a new product and service portfolio.

STERIS (STE) Dips on New Restructuring Plan, Layoff Decision

by Zacks Equity Research

STERIS (STE) aims to stop the production of the worst-hit products and move toward the existing manufacturing operations by fiscal 2020.